GlassScriptPhysician profile
Loris Z Harris
NPI 1922565860
$2,481.61
in general payments reported to CMS, 2019-2025
25 companies · $786 in 2025
The $786 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $589 · 2024: $1,107 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,481.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $452.28 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $294.63 | 2023-2025 | |
| Novo Nordisk INC | $290.84 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $272.80 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $225.84 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $171.08 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $101.25 | 2023-2024 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.25 | 2023-2025 | Xifaxan, Trulance |
| Amgen INC. | $70.65 | 2024-2025 | Otezla, Repatha, Otezla |
| Axsome Therapeutics, INC. | $69.54 | 2023-2025 | Auvelity, Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.87 | 2023-2024 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $46.86 | 2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $43.68 | 2023-2024 | Gardasil 9, Gardasil, Capvaxive |
| Pfizer INC. | $42.26 | 2025 | |
| Idorsia Pharmaceuticals US INC | $31.92 | 2024 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $30.13 | 2024-2025 | Jatenzo |
| Dexcom, INC. | $27.76 | 2024 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $26.85 | 2023 | Austedo Xr |
| Dynavax Technologies Corporation | $23.01 | 2025 | Heplisav-B |
| Lundbeck LLC | $22.91 | 2025 | Rexulti |
| Phadia US INC. | $21.68 | 2024 | Immunocap |
| Daiichi Sankyo INC. | $21.04 | 2023 | Injectafer |
| Inspire Medical Systems, INC. | $20.57 | 2023 | Inspire |
| Scilex Pharmaceuticals INC. | $19.48 | 2023 | Ztlido |
| Shield Therapeutics INC | $16.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loris Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.